Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Mon Feb 2, 3:05PM CST

FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted...

TERN : 37.79 (+0.11%)
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 3:05PM CST

CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated...

TERN : 37.79 (+0.11%)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Fri Jan 2, 3:05PM CST

FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted...

TERN : 37.79 (+0.11%)
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Thu Dec 11, 2025

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of...

TERN : 37.79 (+0.11%)
Terns Announces Pricing of Upsized $650 Million Public Offering GlobeNewswire - Tue Dec 9, 2025

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of...

TERN : 37.79 (+0.11%)
Terns Announces Proposed Public Offering GlobeNewswire - Tue Dec 9, 2025

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced...

TERN : 37.79 (+0.11%)
Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting GlobeNewswire - Mon Dec 8, 2025

64% MMR achievement by 24 weeks across all efficacy evaluable patients  75% MMR achievement by 24 weeks in efficacy evaluable patients at doses > 320mg QD Encouraging safety/tolerability profile...

TERN : 37.79 (+0.11%)
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London GlobeNewswire - Fri Nov 14, 2025

FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of...

TERN : 37.79 (+0.11%)
Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire - Mon Nov 10, 2025

Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract  Upcoming ASH oral presentation to feature expanded and updated dataset from...

TERN : 37.79 (+0.11%)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Tue Nov 4, 2025

FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted...

TERN : 37.79 (+0.11%)

Barchart Exclusives

Is This Metal the Next Big Thing After a Record Silver Rally? 1 ETF to Buy Now. Barchart - 25 minutes ago
After silver’s record rally, nickel might be the next in line. Therefore, the Sprott Nickel Miners ETF may be the fund to buy now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot